Safety and Procedural Success of Left Atrial Appendage Exclusion With the Lariat Device: A Systematic Review of Published Reports and Analytic Review of the FDA MAUDE Database.
OBJECTIVE
The Lariat device has received US Food and Drug Administration (FDA) 510(k) clearance for soft-tissue approximation and is being widely used off-label for left atrial appendage (LAA) exclusion. A comprehensive analysis of safety and effectiveness has not been reported.


OBJECTIVE
To perform a systematic review of published literature to assess safety and procedural success, defined as successful closure of the LAA during the index procedure, of the Lariat device. We performed a formal analytic review of the FDA MAUDE (Manufacturer and User Facility Device Experience) database to compile adverse event reports from real-world practice with the Lariat.


METHODS
For the systematic review, PubMed, EMBASE, CINAHL, and the Cochrane Library were searched from January 2007 through August 2014 to identify all studies reporting use of the Lariat device in 3 or more patients. The FDA MAUDE database was queried for adverse events reports related to Lariat use.
Data were abstracted in duplicate by 2 physician reviewers. Events from published literature were pooled using a generic inverse variance weighting with a random effects model. Cumulative and individual adverse events were also reported using the FDA MAUDE data set.


METHODS
Procedural adverse events and procedural success.


RESULTS
In the systematic review, 5 reports of Lariat device use in 309 participants were identified. Specific complications weighted for inverse of variance of individual studies were urgent need for cardiac surgery (2.3%; 7 of 309 procedures) and death (0.3%; 1 of 309 procedures). Procedural success was 90.3% (279 of 309 procedures). In the FDA MAUDE database, there were 35 unique reports of adverse events with use of the Lariat device. Among these, we identified 5 adverse event reports that noted pericardial effusion and death and an additional 23 reported urgent cardiac surgery without mention of death.


CONCLUSIONS
This review of published reports and case reports identified risks of adverse events with off-label use of the Lariat device for LAA exclusion. Formal, controlled investigations into the safety and efficacy of the device for this indication are warranted.
Division of Cardiology, St Lukes-Roosevelt Hospital Center of the Mount Sinai Health System, New York, New York.
Saurav
S
Chatterjee
Cardiovascular Medicine Division, University of Pennsylvania Perelman School of Medicine, Philadelphia.
Howard C
HC
Herrmann
Cardiovascular Medicine Division, University of Pennsylvania Perelman School of Medicine, Philadelphia.
Robert L
RL
Wilensky
Cardiovascular Medicine Division, University of Pennsylvania Perelman School of Medicine, Philadelphia.
John
J
Hirshfeld
Cardiovascular Medicine Division, University of Pennsylvania Perelman School of Medicine, Philadelphia.
Daniel
D
McCormick
Cardiovascular Medicine Division, University of Pennsylvania Perelman School of Medicine, Philadelphia.
David S
DS
Frankel
Division of Cardiology, Massachusetts General Hospital, Boston.
Robert W
RW
Yeh
Division of Cardiology, University of Colorado, Denver.
Ehrin J
EJ
Armstrong
Division of Cardiology, University of Texas-Southwestern Medical School, Dallas.
Dharam J
DJ
Kumbhani
Cardiovascular Medicine Division, University of Pennsylvania Perelman School of Medicine, Philadelphia.
Jay
J
Giri
D020517:Atrial Appendage / Q000601:surgery*; D001281:Atrial Fibrillation / Q000601:surgery*; D006348:Cardiac Surgical Procedures / Q000295:instrumentation*; D006801:Humans; D019060:Minimally Invasive Surgical Procedures / Q000295:instrumentation